对转诊前直肠青蒿琥酯的错误指控进一步延迟了这种救命药物的推广
十多年前已发现,在重症疟疾患者接受肠外和口服巩固治疗前给予直肠青蒿琥酯栓剂可降低死亡率。2022年1月27日,WHO基于主要在尼日利亚、乌干达和刚果民主共和国开展的观察性研究结果,建议暂停部署直肠青蒿琥酯,从而停止了这一救命干预措施的推广。本文认为该研究及其分析存在方法学缺陷,为研究结果提供了替代解释,并呼吁按原定意图提供直肠青蒿琥酯。
要点
- 十多年前发现转诊前直肠青蒿琥酯可降低重症疟疾死亡率。
- WHO于2022年1月27日基于观察性研究建议暂停部署直肠青蒿琥酯。
- 本文认为该研究采用前后对照设计且存在方法学缺陷,结果有替代解释。
核心结论
- 本文认为不应进一步延迟直肠青蒿琥酯的推广,而应紧急协调努力按原定意图在需要的时间和地点提供该药。
研究设计与样本
- 本文为针对WHO暂停部署直肠青蒿琥酯决定的评论文章,引用了一项在尼日利亚、乌干达和刚果民主共和国开展的观察性研究(CARAMAL项目的一部分)。
主要发现
- 十多年前发现,在重症疟疾患者接受肠外和口服巩固治疗前给予直肠青蒿琥酯栓剂可降低死亡率。
- 2022年1月27日,WHO建议暂停部署直肠青蒿琥酯,该决定主要基于一项观察性研究的结果。
- 该观察性研究采用前后对照设计,发现直肠青蒿琥酯推广后重症疟疾病死率反而升高而非降低。
- 本文认为该研究及其分析存在方法学缺陷,为研究结果提供了替代解释。
临床怎么用
- 本文呼吁按原定意图提供直肠青蒿琥酯,在需要的时间和地点使用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Administering rectal artesunate suppositories to patients with severe malaria before they receive parenteral and oral consolidation therapy was found to reduce mortality more than a decade ago. The roll-out of rectal artesunate could combat the current global increase in malaria deaths. Instead, on Jan 27, 2022, WHO recommended a moratorium on the deployment of rectal artesunate and in doing so stopped the roll-out of a lifesaving intervention. This decision was based mainly on the results from an observational study that is part of a larger project being conducted in Nigeria, Uganda, and DR Congo. The Community Access to Rectal Artesunate for Malaria (CARAMAL) project was not set up to provide patient transport to referral health-care centres for parenteral artesunate administration or logistic support to assure the availability of parenteral and oral antimalarial consolidation therapy. Using a before-after study design, which is known to be prone to bias, the study found that case fatality rates of severe malaria increased instead of decreased after the roll-out of rectal artesunate. However, the study and its analysis have methodological flaws that provide an alternative explanation for study findings. Instead of further delaying the roll-out of rectal artesunate, there is an urgent need for a concerted effort to provide rectal artesunate as originally intended, where and when it is needed.
引用
- von Seidlein L. The wrongful indictment of pre-referral rectal artesunate further delays the roll-out of this lifesaving drug. Lancet Infect Dis. 2022. PMID: 36549312. doi:10.1016/S1473-3099(22)00765-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。